Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 259-270

  Hongrapipat, J ^a,b   Kopeckova P ^a   Prakongpan, S ^b   Kopecek J ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Department of Electrical and Computer Engineering   (United States)

Author keywords

2,5 bis(6 hydroxymethyl 2 thienyl)furan; Combination index; Doxorubicin; Mesochlorin e6 monoethylenediamine; N (2 Hydroxypropyl)methacrylamide (HPMA) copolymer; Renal cancer

Indexed keywords

2,5 BIS(6 HYDROXYMETHYL 2 THIENYL)FURAN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; COPOLYMER; DOXORUBICIN; MESOCHLORIN E6 MONOETHYLENEDIAMINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; N(2 HYDROXYPROPYL)METHACRYLAMIDE GLYCYLPHENYLALANYLLEUCYLGLYCINE 2,5 BIS(6 HYDROXYMETHYL 2 THIENYL)FURAN CONJUGATE; N(2 HYDROXYPROPYL)METHACRYLAMIDE GLYCYLPHENYLALANYLLEUCYLGLYCINE DOXORUBICIN CONJUGATE; N(2 HYDROXYPROPYL)METHACRYLAMIDE GLYCYLPHENYLALANYLLEUCYLGLYCINE MESOCHLORIN E6 MONOETHYLENEDIAMINE CONJUGATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL GROWTH; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FURANS; HUMANS; MESOPORPHYRINS; METHACRYLATES;

EID: 38749144812     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.018     Document Type: Article

References (87)

1. Alley M.C., Hollingshead M.G., Dykes D.J., and Waud W.R. Human tumor xenograft models in NCI drug development. In: Teicher B.A., and Andrews P.A. (Eds). Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (2004), Humana Press, NJ 125-152
2. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann. Oncol. 16 (2005) 7-15
3. Bartoszek A. Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects. Acta Biochim. Pol. 49 (2002) 323-331
4. Berlin V., and Haseltine W.A. Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J. Biol. Chem. 256 (1981) 4747-4756
5. Blagosklonny M.V. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21 (2002) 6249-6254
6. Brophy P.F., and Keller S.M. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J. Surg. Res. 52 (1992) 631-634
7. Buchegger F., Allal A.S., Roth A., Papazyan J.P., Dupertuis Y., Mirimanoff R.O., Gillet M., Pelegrin A., Mach J.P., and Slosman D.O. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: a feasibility study. Anticancer Res. 20 (2000) 1889-1896
8. Chiarello K. In between the light and the dark. Pharm. Technol. 28 (2004) 48-54
9. Chou T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59 (1976) 253-276
10. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006) 621-681
11. 50 Values (2006), ComboSyn Inc., New York
12. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
13. Colasanti A., Kisslinger A., Quarto M., and Riccio P. Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model. Acta Biochim. Pol. 51 (2004) 1039-1046
14. Dasmahapatra G.P., Didolkar P., Alley M.C., Ghosh S., Sausville E.A., and Roy K.K. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin. Cancer Res. 10 (2004) 5242-5252
15. Dolmans D.E., Fukumura D., and Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 3 (2003) 380-387
16. Dougherty T.J., Cooper M.T., and Mang T.S. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg. Med. 10 (1990) 485-488
17. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
18. Duncan R., Rejmanová P., Kopeček J., and Lloyd J.B. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta 678 (1981) 143-150
19. Edell E.S., and Cortese D.A. Combined effects of hematoporphyrin derivative phototherapy and adriamycin in a murine tumor model. Lasers Surg. Med. 8 (1988) 413-417
20. Fischer P.M., and Lane D.P. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?. Trends Pharmacol. Sci. 25 (2004) 343-346
21. Fornari F.A., Randolph J.K., Yalowich J.C., Ritke M.K., and Gewirtz D.A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45 (1994) 649-656
22. Frei III E., Karon M., Levin R.H., Freireich E.J., Taylor R.J., Hananian J., Selawry O., Holland J.F., Hoogstraten B., Wolman I.J., Abir E., Sawitsky A., Lee S., Mills S.D., Burgert Jr. E.O., Spurr C.L., Patterson R.B., Ebaugh F.G., James III G.W., and Moon J.H. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26 (1965) 642-656
23. Goff B.A., Bamberg M., and Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 51 (1991) 4762-4767
24. Greco F., Vicent M.J., Penning N.A., Nicholson R.I., and Duncan R. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Target. 13 (2005) 459-470
25. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., and Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23 (2005) 7889-7896
26. Hansen M.B., Nielsen S.E., and Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119 (1989) 203-210
27. Harris S.M., Mistry P., Freathy C., Brown J.L., and Charlton P.A. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br. J. Cancer 92 (2005) 722-728
28. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 1 (2000) 212-219
29. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
30. Jin M.L., Yang B.Q., Zhang W., and Ren P. Combined treatment with photodynamic therapy and chemotherapy for advanced cardiac cancers. J. Photochem. Photobiol. B 12 (1992) 101-106
31. Kim W.J., Kakehi Y., Kinoshita H., Arao S., Fukumoto M., and Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J. Urol. 156 (1996) 506-511
32. Kirveliene V., Grazeliene G., Dabkeviciene D., Micke I., Kirvelis D., Juodka B., and Didziapetriene J. Schedule-dependent interaction between doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother. Pharmacol. 57 (2006) 65-72
33. Kopeček J. Controlled biodegradability of polymers-a key to drug delivery systems. Biomaterials 5 (1984) 19-25
34. Kopeček, J., Krinick, N.L., 1993. Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light. US Patent 5,258,453, November 2.
35. Kopeček J., and Rejmanová P. Enzymatically degradable bonds in synthetic polymers. In: Bruck S.D. (Ed). Controlled Drug Delivery vol. 1 (1983), CRC Press, FL 81-124
36. Kopeček, J., Rejmanová, P., Strohalm, J., Ulbrich, K., Říhová, B., Chytrý, V., Lloyd, J., Duncan, R., 1991. Synthetic polymeric drugs. US Patent 5,037,883 (August 6).
37. Kopeček J., Kopečková P., Minko T., and Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50 (2000) 61-81
38. 6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol. Chem. 191 (1990) 839-856
39. Krinick N.L., Sun Y., Joyner D., Spikes J.D., Straight R.C., and Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. 5 (1994) 303-324
40. Lanks K.W., Gao J.P., and Sharma T. Photodynamic enhancement of doxorubicin cytotoxicity. Cancer Chemother. Pharmacol. 35 (1994) 17-20
41. Larsen A.K., Escargueil A.E., and Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog. Cell Cycle Res. 5 (2003) 295-300
42. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-290
43. 6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int. J. Oncol. 15 (1999) 5-16
44. Malugin A., Kopečková P., and Kopeček J. HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function. Mol. Pharm. 3 (2006) 351-361
45. Mertins S.D., Myers T.G., Hollingshead M., Dykes D., Bodde E., Tsai P., Jefferis C.A., Gupta R., Linehan W.M., Alley M., and Bates S.E. Screening for and identification of novel agents directed at renal cell carcinoma. Clin. Cancer Res. 7 (2001) 620-633
46. Mickisch G., Bier H., Bergler W., Bak M., Tschada R., and Alken P. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol. Int. 45 (1990) 170-176
47. Minko T., Kopečková P., Pozharov V., and Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Rel. 54 (1998) 223-233
48. Minko T., Kopečková P., and Kopeček J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Rel. 59 (1999) 133-148
49. Minko T., Kopečková P., and Kopeček J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86 (2000) 108-117
50. Minko T., Kopečková P., and Kopeček J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol. Symp. 172 (2001) 35-47
51. Nahabedian M.Y., Cohen R.A., Contino M.F., Terem T.M., Wright W.H., Berns M.W., and Wile A.G. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J. Natl. Cancer Inst. 80 (1988) 739-743
52. Neidle S. The molecular basis for the action of some DNA-binding drugs. Prog. Med. Chem. 16 (1979) 151-221
53. Nieves-Neira W., Rivera M.I., Kohlhagen G., Hursey M.L., Pourquier P., Sausville E.A., and Pommier Y. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol. Pharmacol. 56 (1999) 478-484
54. Nishiyama N., Nori A., Malugin A., Kasuya Y., Kopečková P., and Kopeček J. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res. 63 (2003) 7876-7882
55. 6 monoethylene diamine in human epithelial ovarian carcinoma (OVCAR-3) in vitro. J. Soc. Gynecol. Invest. 2 (1995) 772-777
56. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.G., Straight R.C., and Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56 (1996) 3980-3985
57. Poindessous V., Koeppel F., Raymond E., Cvitkovic E., Waters S.J., and Larsen A.K. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Int. J. Oncol. 23 (2003) 1347-1355
58. Putnam D., and Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122 (1995) 55-123
59. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., Beijnen J.H., Schellens J.H., and Droz J.P. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 10 (2004) 3386-3395
60. Rejmanová P., Pohl J., Baudyš M., Kostka V., and Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184 (1983) 2009-2020
61. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., and Kopeček J. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46 (1988) 100-114
62. Říhová B., Strohalm J., Hoste K., Jelínková M., Hovorka O., Kovář M., Plocová D., Šírová M., Št'astný M., Schacht E., and Ulbrich K. Immunoprotective therapy with targeted anticancer drugs. Macromol. Symp. 172 (2001) 21-28
63. Rivera M.I., Stinson S.F., Vistica D.T., Jorden J.L., Kenney S., and Sausville E.A. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem. Pharmacol. 57 (1999) 1283-1295
64. Sachdeva, K., 2006. Renal cell carcinoma. http://www.emedicine.com/med/topic2002.htm#sectiontreatment.
65. Saucier J.M., Yu J., Gaikwad A., Coleman R.L., Wolf J.K., and Smith J.A. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J. Oncol. Pharm. Pract. 13 (2007) 39-45
66. Seymour L.W., Duncan R., Strohalm J., and Kopeček J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21 (1987) 1341-1358
67. Seymour L.W., Ulbrich K., Strohalm J., Kopeček J., and Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39 (1990) 1125-1131
68. Shan K., Lincoff A.M., and Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125 (1996) 47-58
69. Shanks R.H., Rizzieri D.A., Flowers J.L., Colvin O.M., and Adams D.J. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin. Cancer Res. 11 (2005) 4225-4233
70. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Control. Rel. 61 (1999) 145-157
71. 6 and adriamycin conjugates in combination treatments. Clin. Cancer Res. 6 (2000) 1008-1015
72. Shiah J.G., Dvořák M., Kopečková P., Sun Y., Peterson C.M., and Kopeček J. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice. Eur. J. Cancer 37 (2001) 131-139
73. 6-OV-TL 16 antibody immunoconjugates. J. Control. Rel. 74 (2001) 249-253
74. Sinha B.K., Katki A.G., Batist G., Cowan K.H., and Myers C.E. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 26 (1987) 3776-3781
75. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., and Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226 (1984) 466-468
76. Topaly J., Fruehauf S., Ho A.D., and Zeller W.J. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br. J. Cancer 86 (2002) 1487-1493
77. Trail P.A., Willner D., Bianchi A.B., Henderson A.J., TrailSmith M.D., Girit E., Lasch S., Hellström I., and Hellström K.E. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin. Cancer Res. 5 (1999) 3632-3638
78. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., and Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterization. J. Control. Rel. 64 (2000) 63-79
79. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5 (1999) 83-94
80. Vicent M.J., Greco F., Nicholson R.I., Paul A., Griffiths P.C., and Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. Engl. 44 (2005) 4061-4066
81. Vugrin D. Systemic therapy of metastatic renal cell carcinoma. Semin. Nephrol. 7 (1987) 152-162
82. Warburton H.E., Brady M., Vlatkovic N., Linehan W.M., Parsons K., and Boyd M.T. p53 regulation and function in renal cell carcinoma. Cancer Res. 65 (2005) 6498-6503
83. Welt S., Ritter G., Williams Jr. C., Cohen L.S., Jungbluth A., Richards E.A., Old L.J., and Kemeny N.E. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 9 (2003) 1347-1353
84. Yamashita Y., Krauze M.T., Kawaguchi T., Noble C.O., Drummond D.C., Park J.W., and Bankiewicz K.S. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-Oncol. 9 (2007) 20-28
85. Yu D.S., Chang S.Y., and Ma C.P. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br. J. Urol. 82 (1998) 544-547
86. Zhang L., Yu D., Hicklin D.J., Hannay J.A., Ellis L.M., and Pollock R.E. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 62 (2002) 2034-2042
87. Zhao L., Wientjes M.G., and Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin. Cancer Res. 10 (2004) 7994-8004